Key Points
- Director Yann Echelard sold 5,000 TG Therapeutics shares on Nov. 24 at an average price of $32.57 for proceeds of $162,850, reducing his stake by about 2.19% to 223,816 shares; the sale was disclosed in an SEC filing.
- TG Therapeutics reported a strong quarter with EPS of $2.43 (vs. $0.24 consensus) and revenue of $161.71 million, up 92.7% year‑over‑year, while the stock trades with a market cap around $5.24 billion and a PE of ~89.
- Analysts hold a consensus rating of “Moderate Buy” with a $50.25 average target after several upgrades (including HC Wainwright, B. Riley and JPMorgan), and institutional investors now own about 58.6% of the shares.
TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the sale, the director owned 223,816 shares in the company, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
TG Therapeutics Stock Performance
NASDAQ:TGTX opened at $32.98 on Wednesday. The firm has a market capitalization of $5.24 billion, a PE ratio of 89.14 and a beta of 1.95. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $46.48. The firm has a 50-day moving average price of $33.81 and a 200 day moving average price of $33.92.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. During the same period in the previous year, the business earned $0.02 earnings per share. The company's quarterly revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
Analyst Ratings Changes
TGTX has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They issued a "buy" rating and a $60.00 price target on the stock. B. Riley upgraded TG Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday, November 19th. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $46.00 to $49.00 and gave the stock an "overweight" rating in a research note on Monday, November 3rd. Finally, Wall Street Zen upgraded TG Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.25.
Read Our Latest Research Report on TGTX
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Penn Capital Management Company LLC boosted its position in TG Therapeutics by 17.6% in the 3rd quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company's stock valued at $18,877,000 after buying an additional 77,895 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of TG Therapeutics during the third quarter worth $559,000. Danske Bank A S acquired a new position in shares of TG Therapeutics during the third quarter valued at $25,000. NewEdge Advisors LLC lifted its stake in shares of TG Therapeutics by 14.4% during the third quarter. NewEdge Advisors LLC now owns 8,687 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 1,094 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in TG Therapeutics by 13.2% in the third quarter. CANADA LIFE ASSURANCE Co now owns 132,284 shares of the biopharmaceutical company's stock valued at $4,872,000 after acquiring an additional 15,396 shares during the last quarter. Institutional investors own 58.58% of the company's stock.
TG Therapeutics Company Profile
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
